until more trial data become available. Talha Khan Burki reports. Last month, US regulators informed AstraZeneca and Bristol-Myers Squibb that they are not yet able to approve dapagliflozin, an oral antidiabetic drug on which the two companies are partnered.

battle with two heavyweight drugmakers over blood thinner Plavix. Apotex Corp., Canadas biggest drugmaker, has paid Bristol-Myers Squibb Co. and Sanofi SA, the two brand-name drugmakers that jointly sell Plavix, $442.2 million in damages ordered over its improper

the same website at the start of the live webcast. An archived edition of the presentation will be available later that day. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that

patent infringement battle over blood thinner Plavix ends with generic drugmaker Apotex Corp. paying about $445 million to Bristol-Myers Squibb and Sanofi. They jointly sell the world's second-best-selling drug. GENERICS COMING: Plavix gets U.S. generic competition

has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix back in 2006. The payment marks the end of a patent dispute that went

Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report

the outlook for one of Israel’s biggest trading partners. Teva said on Jan. 2 that Jeremy Levin, formerly of drugmaker Bristol-Myers Squibb Co., will replace Shlomo Yanai as chief executive after U.S.-traded shares plunged 23 percent last year, the most since

earning power can be very attractive to investors seeking out stable holdings. At the current time, Ameren Corp, Bristol-Myers Squibb, Duke Energy Corp and Exelon Corp all seem to be very good ideas for purchase. Although it is a very good company, investors

the release of the fourth quarter 2011 results, majority of the analysts covering Bristol-Myers Squibb Company (BMY) lowered their earnings estimates for fiscal 2012. The pharma major reported lower-than-expected earnings and revenues in the final quarter

been lowering expectations. Analysts have been fearing that competition from generic forms of Plavix (once marketed by Bristol-Myers Squibb (BMY) and Sanofi (SNY)) would cut into Brillinta, and it looks like that may be true. That may well only add fuel to